PER-086-13未知未知
A DOSE-BLINDED, 2-DOSE LEVEL, PARALLEL-GROUP, MULTICENTER, LONG-TERM EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, EFFICACY, AND IMMUNOGENICITY OF BIIB023 IN SUBJECTS WITH LUPUS NEPHRITIS
适应症
试验速览
- 阶段
- 未知
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.
- •2. Subjects who completed Week 52 of Study 211LE201 and did not discontinue BIIB023 or placebo study treatment.
- •3. Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 6 months after their last dose of study treatment.
排除标准
- •1. Any significant change in medical history in subjects from Study 211LE201, including laboratory tests or current clinically significant condition that, in the opinion of the Investigator, would have excluded the subjects’ participation.
- •2. Subjects from Study 211LE201 who discontinued BIIB023 or placebo treatment prior to Week 52 of Study 211LE201.
- •3. Female subjects considering becoming pregnant while in the study, currently pregnant, or breast feeding.
- •4. Previous participation in Study 211LE202; subjects who were enrolled in Study 211LE202 and consequently withdrew for any reason are prohibited from re-entering the study.
- •5. Unwillingness or inability to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject’s ability to comply with the protocol.
- •6. Subjects who were prescribed MMF >3 g/day during Study 211LE201 and/or subjects for whom the Investigator is planning to prescribe MMF >3 g/day during this study.
- •7. Subjects having received disallowed concomitant medication during Study 211LE201 including the items detailed in the protocol page N° 20
- •8. Subjects with the following laboratory test results at Week 48 of Study 211LE201including the items detailed in the protocol page N° 20 and 21.
- •9. Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, makes the subject unsuitable for enrollment.
研究者
相似试验
进行中（未招募）
不适用
ong-Term Extension Study of BIIB023 in Subjects with Lupus Nephritisupus NephritisMedDRA version: 18.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000594-69-HUBiogen Idec Research Limited220
进行中（未招募）
不适用
ong-Term Extension Study of BIIB023 in Subjects with Lupus Nephritisupus NephritisMedDRA version: 17.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000594-69-PLBiogen Idec Research Limited220
进行中（未招募）
不适用
ong-Term Extension Study of BIIB023 in Subjects with Lupus Nephritisupus NephritisMedDRA version: 17.0Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000594-69-PTBiogen Idec Research Limited220
进行中（未招募）
1 期
ong-Term Extension Study of BIIB023 in Subjects with Lupus NephritisEUCTR2013-000594-69-BEBiogen Idec Research Limited220
进行中（未招募）
不适用
ong-Term Extension Study of BIIB023 in Subjects with Lupus Nephritisupus NephritisMedDRA version: 16.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-000594-69-ESBiogen Idec Research Limited220